


## CK1-IN-3

<b>Cat. No.:</b>	HY-128433
<b>CAS No.:</b>	349438-74-0
<b>Molecular Formula:</b>	C <sub>17</sub> H <sub>16</sub> N <sub>2</sub> O <sub>3</sub> S
<b>Molecular Weight:</b>	328.39
<b>Target:</b>	Casein Kinase
<b>Pathway:</b>	Cell Cycle/DNA Damage; Stem Cell/Wnt
<b>Storage:</b>	-20°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 125 mg/mL (380.64 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	3.0452 mL	15.2258 mL	30.4516 mL
	5 mM	0.6090 mL	3.0452 mL	6.0903 mL
	10 mM	0.3045 mL	1.5226 mL	3.0452 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

CK1-IN-3 (compound 51) is a AC1 inhibitor with an IC<sub>50</sub>s 2.22 μM for CK-1δ<sup>[1][2]</sup>.

#### IC<sub>50</sub> & Target

CK1δ  
2.22 μM (IC<sub>50</sub>)

#### In Vivo

CK1-IN-3 (compound 35) (100 nM; feed) significantly extends fly lifespan to 36.17 days<sup>[2]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Ana MARTÍNEZ GIL, et al. Substituted benzothiazoles and therapeutic uses thereof for the treatment of human diseases. WO2014114825A1.
- [2]. Salado IG, et al. Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis. J Med Chem. 2014 Mar 27;57(6):2755-72.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA